Thursday
October
30
2014
10:05 pm
Weather

  Home
  Local News
  State / National / World
  Sports
  Opinion / Letters
  Business
  Arts / Entertainment
  Lifestyle
  Obituaries
  Calendar
  Submit Event
  Comics / Games
  Classifieds
  DJ Designers
  Archives
  Advertise With Us
  About Us
 
 
 
 

Check out our archive of Dining Guides - Yum!

Amgen misses 1Q views as higher costs cut profit
April 23, 2014, 05:00 AM The Associated Press

Despite higher sales, biotech drugmaker Amgen’s first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed Wall Street’s expectations for both earnings per share and revenue, sending down its shares.

The maker of injected osteoporosis treatment Prolia said Tuesday that net income was $1.07 billion or $1.40 per share, down from $1.43 billion, or $1.88 per share, in 2013’s first quarter.

Excluding one-time items, income would have been $1.44 billion, or $1.87 per share. Analysts expected $1.94.

Revenue totaled $4.52 billion, up 7 percent. Analysts were expecting $4.76 billion.

Sales were led by Neulasta and Neupogen for boosting infection-fighting white blood cells, up about 3 percent to a combined $1.38 billion. Sales of immune disorder drug Enbrel, Amgen’s N. 2 seller, fell 5 percent to $988 million.

Sales of six other medicines were up at least slightly, led by a 38 percent jump in Prolia sales to $196 million. Prolia is touted in TV ads by actress Blythe Danner.

The company, based in Thousand Oaks, Calif., noted that the 17 percent increase in research and development spending, to $1.03 billion in the quarter, was mainly due to expenses to continue the research programs of Onyx Pharmaceuticals, the South San Francisco cancer drug company it acquired last October.

“Strong underlying demand for our products and growth in adjusted operating income make us confident in our full-year growth outlook,” CEO Robert Bradway said in a statement, adding, “We continue to advance our robust late-stage pipeline.”

The company reiterated its 2014 financial forecasts, for adjusted earnings per share of $7.90 to $8.20 and revenue of $19.2 billion to $19.6 billion. Analysts surveyed by FactSet expect earnings per share of $8.15 on revenue of $19.62 billion.

In after-hours trading, Amgen shares slipped $3.25, or 2.7 percent, to $116.05.

 

 

Tags: billion, percent, share, sales, quarter, company,


Other stories from today:

 

 
Print this Page Print this Page  |  Bookmark and Share
<< Back
 
Return To Archives
 
  


 
 
 
Daily Journal Quick Poll
 
Now that the Giants have won three World Series titles in five years, would you say they are a dynasty?

Absolutely, yes
I would think so
Maybe one more would make them a dynasty
I don't like the word dynasty
Madison Bumgarner is a dynasty!

 

 
 
 
 
 
 
Multiple officers injured during World Series victory celebrations
Multiple San Francisco police officers were injured while attempting to disperse crowds and extingui..
Protesters storm Burkina Faso parliament, set fire
OUAGADOUGOU, Burkina Faso — Protesters stormed Burkina Faso's parliament Thursday, dragging furnit..
Maine nurse defies Ebola quarantine with bike ride
FORT KENT, Maine — A nurse who vowed to defy Maine's voluntary quarantine for health care workers ..
More >>  
 
 
  
 
  
 
©2014 San Mateo Daily Journal
Half Moon Bay news